TP53 mutation is a biomarker for prognosis in triple-negative breast cancer patients treated with post-neoadjuvant cisplatin

被引：0

作者：

Hancock, B. A. ^{[1
]}

Chen, Y-H ^{[1
]}

Solzak, J. P. ^{[1
]}

Miller, K. D. ^{[1
]}

Radovich, M. ^{[1
]}

机构：

[1] Indiana Univ Sch Med, Indianapolis, IN 46202 USA

来源：

CANCER RESEARCH | 2016年 / 76卷

关键词：

D O I：

10.1158/1538-7445.SABCS15-P2-08-23

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2-08-23

引用

页数：1

共 50 条

[1] TP53 mutation is a biomarker for prognosis in triple-negative breast cancer patients treated with post-neoadjuvant cisplatin
Hancock, Bradley
Chen, Yu-Hsiang
Solzak, Jeffrey
Miller, Kathy
Radovich, Milan
[J]. CANCER RESEARCH, 2016, 76
[2] TP53 mutation in triple negative breast cancer
Nikolaidou, A.
Botsfari, E.
Goupou, E.
Rouptsiou, E.
Iosifidou, R.
Patakiouta, F.
[J]. VIRCHOWS ARCHIV, 2017, 471 : S302 - S302
[3] Association of TP53 codon 72 polymorphism with TP53mutation in triple-negative breast cancer (TNBC) patients.
Foedermayr, Mathilde
Sebesta, Miriam
Rudas, Margaretha
Berghoff, Anna Sophie
Bergen, Elisabeth
Promberger, Regina
Preusser, Matthias
Dubsky, Peter Christian
Gnant, Michael
Steger, Guenther G.
Weltermann, Ansgar
Zielinski, Christoph
Zach, Otto
Bartsch, Rupert
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] TP53 Signature Score Predicts Prognosis and Immune Response in Triple-negative Breast Cancer
Onishi, Mai
Yamaguchi, Shigeo
Wen, Xuan
Han, Min
Kido, Hidenori
Aruga, Tomoyuki
Horiguchi, Shin-ichiro
Kato, Shunsuke
[J]. ANTICANCER RESEARCH, 2023, 43 (04) : 1731 - 1739
[5] BRCAness and prognosis in triple-negative breast cancer patients treated with neoadjuvant chemotherapy
Tanino, Hirokazu
Kosaka, Yoshimasa
Sengoku, Norihiko
Waraya, Mina
Nishimiya, Hiroshi
Katoh, Hirozhi
Kikuchi, Mariko
Minatani, Naoko
Teraoka, Saeko
Enomoto, Takumo
Sato, Takeo
Masahiko, Masahiko
[J]. CANCER RESEARCH, 2015, 75
[6] BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Tanino, Hirokazu
Kosaka, Yoshimasa
Nishimiya, Hiroshi
Tanaka, Youko
Minatani, Naoko
Kikuchi, Mariko
Shida, Akiko
Waraya, Mina
Katoh, Hiroshi
Enomoto, Takumo
Sengoku, Norihiko
Kajita, Sabine
Hoffman, Robert M.
Watanabe, Masahiko
[J]. PLOS ONE, 2016, 11 (12):
[7] The impact of TP53 mutation and pathological response to neoadjuvant chemotherapy on triple negative breast cancer outcomes
Mitri, Zahi
Lin, Chih-Hsu
Hess, Kenneth R.
Thompson, Alastair
Lichtarge, Olivier
Hubbard, Rebekah
Fu, Chunxiao
Symmans, William F.
Moulder-Thompson, Stacy L.
[J]. CANCER RESEARCH, 2018, 78 (04)
[8] Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer
Foedermayr, Mathilde
Sebesta, Miriam
Rudas, Margaretha
Berghoff, Anna S.
Promberger, Regina
Preusser, Matthias
Dubsky, Peter
Gnant, Michael
Steger, Guenther G.
Weltermann, Ansgar
Zielinski, Christoph C.
Zach, Otto
Bartsch, Rupert
[J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2016, 9 (02) : 70 - 75
[9] Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
Kim, Ji-Yeon
Park, Kyunghee
Jung, Hae Hyun
Lee, Eunjin
Cho, Eun Yoon
Lee, Kwang Hee
Bae, Soo Youn
Lee, Se Kyung
Kim, Seok Won
Lee, Jeong Eon
Nam, Seok Jin
Ahn, Jin Seok
Im, Young-Hyuck
Park, Yeon Hee
[J]. CANCER RESEARCH AND TREATMENT, 2016, 48 (04): : 1338 - 1350
[10] BRCAness and prognosis of triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
Akashi-Tanaka, Sadako
Tanino, Yuichi
Yamamoto, Yutaka
Nishimiya, Hiroshi
Yamamoto-ibusuki, Mutsuko
Iwase, Hirotaka
Nakamura, Seigo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →